Quick Answer
ROCKET PHARMACEUTICALS, INC. reported Net Income Loss of -$223.12 million for the year ending 2025.
- ROCKET PHARMACEUTICALS, INC. showed an increase of +13.8% in Net Income Loss from 2024 to 2025.
- This data is from ROCKET PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 12 years of available data (2014 to 2025), ROCKET PHARMACEUTICALS, INC.'s Net Income Loss has declined by 2,241.0%.
- Historical annual values: Fiscal year 2025: -$223.12 million | Fiscal year 2024: -$258.75 million | Fiscal year 2023: -$245.60 million | Fiscal year 2022: -$221.86 million | Fiscal year 2021: -$169.07 million | Fiscal year 2020: -$139.70 million | Fiscal year 2019: -$77.27 million | Fiscal year 2018: -$74.52 million | Fiscal year 2017: -$19.58 million | Fiscal year 2016: -$7.57 million | Fiscal year 2015: -$67.98 million | Fiscal year 2014: -$9.53 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: